The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2025 | The importance of understanding how patient factors may affect the risk of CAR-T-related toxicities
In this video, Kai Rejeski, MD, Ludwig-Maximilians University, Munich, Germany, briefly discusses how patient-related factors, including age, sex, performance status, and body composition, may contribute to the development of CAR-T-related toxicities. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we talk a lot about the importance of tumor-related features as well as CAR T-cell-related factors when we’re talking about the development of toxicities. But the role of the patient, right? We’re giving CAR T-cell therapy, providing CAR T-cell therapy to the patient that’s in front of us. And so each patient presents to CAR T-cell therapy at a different age. Oftentimes we also see sex-related differences...
So we talk a lot about the importance of tumor-related features as well as CAR T-cell-related factors when we’re talking about the development of toxicities. But the role of the patient, right? We’re giving CAR T-cell therapy, providing CAR T-cell therapy to the patient that’s in front of us. And so each patient presents to CAR T-cell therapy at a different age. Oftentimes we also see sex-related differences. We see differences in performance status. And we’re understanding more and more that the host, the patient in front of us, plays an important role in sort of driving the risk for developing treatment-related toxicities. And so I think understanding that role, understanding the role of body composition, of physical fitness, understanding the role of the microbiome and other sort of host-related features, I think that’s really going to be an area of active research in the coming years.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Kite/Gilead: Research Funding, Consultancy, Honoraria and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support. CSL Behring: Consultancy
